HNWAG
RAPT

High Net Worth Advisory Group’s RAPT Therapeutics RAPT Stock Holding History

High Net Worth Advisory Group’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-63
Closed -$12K – 678
2022
Q3 		$12K Buy
+63
New +$11.9K 0.01% 515
2022
Q1 		– Sell
-63
Closed -$18K – 718
2021
Q4 		$18K Buy
+63
New +$16.8K 0.01% 476

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

High Net Worth Advisory Group's RAPT Position: Q4 2022 in Review

High Net Worth Advisory Group sold out of RAPT Therapeutics (RAPT) in Q4 2022, closing a stake of 63 shares — an estimated $12K sold.

High Net Worth Advisory Group first reported a position in RAPT in Q4 2021 and held it in 2 quarters. The position peaked at $18K in Q4 2021. 95 funds tracked by Wall St. Rank hold RAPT as of Q4 2022.

  • High Net Worth Advisory Group reported no remaining RAPT Therapeutics position as of Q4 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 63 RAPT Therapeutics shares in Q4 2022, an estimated $12K.
  • High Net Worth Advisory Group first reported a position in RAPT Therapeutics in Q4 2021 and held it in 2 quarters.
  • High Net Worth Advisory Group's RAPT Therapeutics position peaked at $18K in Q4 2021.
  • 95 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2022.

Based on High Net Worth Advisory Group's 13F filing for Q4 2022, filed 14 Feb 2023.